Hepion Stock Analysis

HEPA -  USA Stock  

USD 2.12  0.11  4.93%

The current indifference towards the small price fluctuations of Hepion Pharmaceuticals may raise some interest from investors. The stock closed today at a share price of 2.12 on 1,524,400 in trading volume. The company directors and management did not add any value to Hepion Pharmaceuticals investors in May. However, most investors can still diversify their portfolios with Hepion Pharmaceuticals to hedge their inherited risk against high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 3.89. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Hepion Pharmaceuticals partners.
Please check Risk vs Return Analysis.

Search Stock Analysis 

The Hepion Pharmaceuticals stock analysis report makes it easy to digest most publicly released information about Hepion Pharmaceuticals and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Hepion stock analysis module also helps to analyze the Hepion Pharmaceuticals price relationship with some important fundamental indicators such as market cap and management efficiency.

Hepion Stock Analysis Notes

About 27.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 0.5. Some equities with similar Price to Book (P/B) outperform the market in the long run. Hepion Pharmaceuticals recorded a loss per share of 10.33. The entity had not issued any dividends in recent years. The firm had a split on the 3rd of June 2019. Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey. Hepion Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 13 people. To learn more about Hepion Pharmaceuticals call Robert Foster at 732-902-4000 or check out http://www.hepionpharma.com.

Hepion Pharmaceuticals Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Hepion Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Hepion Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Hepion Pharmaceuticals has very high historical volatility over the last 90 days
Hepion Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (20.36 M).
Hepion Pharmaceuticals currently holds about 40.73 M in cash with (16.17 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.53.
Hepion Pharmaceuticals has a very weak financial position based on the latest SEC disclosures
Latest headline from www.equities.com: Hepion Pharmaceuticals Inc rose 15.3060 percent for June 10 - Equities.com

Hepion Largest EPS Surprises

Earnings surprises can significantly impact Hepion Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

Hepion Pharmaceuticals SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Hepion Pharmaceuticals prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Hepion Pharmaceuticals investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Hepion Pharmaceuticals specific information freely available to individual and institutional investors to make a timely investment decision.
9th of June 2021
Financial Statements and Exhibits. Other Events
6th of May 2021
Financial Statements and Exhibits. Other Events
29th of April 2021
Financial Statements and Exhibits. Other Events
23rd of March 2021
Financial Statements and Exhibits. Other Events
11th of March 2021
Financial Statements and Exhibits. Other Events
24th of February 2021
Unclassified Corporate Event
19th of February 2021
Unclassified Corporate Event
18th of February 2021
Unclassified Corporate Event

Hepion Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Hepion Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Hepion Pharmaceuticals backward and forwards among themselves. Hepion Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Hepion Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Vanguard Group IncCommon Shares3.3 M6.1 M
Blackrock IncCommon Shares1.7 M3.2 M
Geode Capital Management LlcCommon Shares588.7 K1.1 M
Susquehanna International Group LlpPut Options552.6 KM
Susquehanna International Group LlpCall Options354.5 K652 K
Susquehanna International Group LlpCommon Shares353.6 K651 K
Sabby Management LlcCommon Shares306.3 K564 K
Virtu Financial LlcCommon Shares179 K329 K
Gsa Capital Partners LlpCommon Shares160.8 K296 K
Note, although Hepion Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Hepion Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 161.6 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Hepion Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Hepion Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Hepion Profitablity

Hepion Pharmaceuticals' profitability indicators refer to fundamental financial ratios that showcase Hepion Pharmaceuticals' ability to generate income relative to its revenue or operating costs. If, let's say, Hepion Pharmaceuticals is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Hepion Pharmaceuticals' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Hepion Pharmaceuticals' profitability requires more research than a typical breakdown of Hepion Pharmaceuticals' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2021
Return on Average Assets(0.70) (0.75) 
Return on Average Equity(0.90) (0.97) 
Return on Invested Capital(7.21) (7.40) 

Management Efficiency

The entity has return on total asset (ROA) of (36.36) % which means that it has lost $36.36 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (72.51) %, meaning that it created substantial loss on money invested by shareholders. Hepion Pharmaceuticals management efficiency ratios could be used to measure how well hepion pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of June 19, 2021, Return on Average Assets is expected to decline to -0.75. In addition to that, Return on Average Equity is expected to decline to -0.97. Hepion Pharmaceuticals Total Assets are projected to increase significantly based on the last few years of reporting. The past year's Total Assets were at 48.65 Million. The current year Current Assets is expected to grow to about 46 M, whereas Assets Non Current are forecasted to decline to about 5.5 M.
Last ReportedProjected for 2021
Book Value per Share 4.19  5.27 
Enterprise Value over EBIT(1.15) (1.24) 
Enterprise Value over EBITDA(0.34) (0.37) 
Price to Book Value 0.49  0.50 
Tangible Assets Book Value per Share 4.83  4.96 
Enterprise Value6.9 MM
Tangible Asset Value46.8 M50.5 M

Technical Drivers

As of the 19th of June, Hepion Pharmaceuticals retains the Downside Deviation of 4.2, risk adjusted performance of 0.0284, and Market Risk Adjusted Performance of 0.609. Hepion Pharmaceuticals technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for Hepion Pharmaceuticals, which can be compared to its competitors. Please check out Hepion Pharmaceuticals value at risk, and the relationship between the jensen alpha and semi variance to decide if Hepion Pharmaceuticals is priced fairly, providing market reflects its last-minute price of 2.12 per share. Please also validate Hepion Pharmaceuticals total risk alpha, which is currently at (0.12) to confirm the company can sustain itself at a future point.

Hepion Pharmaceuticals Price Movement Analysis

Illegal number of arguments. The output start index for this execution was zero with a total number of output elements of zero. The Exponential Moving Average is calculated by weighting recent values of Hepion Pharmaceuticals more heavily than older values. View also all equity analysis or get more info about exponential moving average overlap studies indicator.

Hepion Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Hepion Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Hepion Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Hepion Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Hepion Pharmaceuticals Predictive Daily Indicators

Hepion Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Hepion Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Hepion Pharmaceuticals Forecast Models

Hepion Pharmaceuticals time-series forecasting models is one of many Hepion Pharmaceuticals' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Hepion Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Hepion Pharmaceuticals Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Hepion Pharmaceuticals stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Hepion shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Hepion Pharmaceuticals. By using and applying Hepion Stock analysis, traders can create a robust methodology for identifying Hepion entry and exit points for their positions.
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing CRV431, a cyclophilin inhibitor that is in Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.

Current Hepion Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Hepion analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Hepion analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
7.0Strong Buy2Odds
Hepion Pharmaceuticals current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Hepion analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Hepion stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Hepion Pharmaceuticals, talking to its executives and customers, or listening to Hepion conference calls.
Hepion Analyst Advice Details

Hepion Stock Analysis Indicators

Hepion Pharmaceuticals stock analysis indicators help investors evaluate how Hepion Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Hepion Pharmaceuticals shares will generate the highest return on investment. By understating and applying Hepion Pharmaceuticals stock analysis, traders can identify Hepion Pharmaceuticals position entry and exit signals to maximize returns.
Quick Ratio8.74
Fifty Two Week Low1.4500
Shares Short Prior Month1.91M
Average Daily Volume Last 10 Day4.08M
Average Daily Volume In Three Month2.39M
Shares Percent Shares Out3.04%
Short Percent Of Float3.04%
Forward Price Earnings-4.24
Float Shares62.65M
Fifty Two Week High4.8300
Enterprise Value To Ebitda-4.50
Fifty Day Average1.7712
Two Hundred Day Average1.9784
Please check Risk vs Return Analysis. Note that the Hepion Pharmaceuticals information on this page should be used as a complementary analysis to other Hepion Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.

Complementary Tools for Hepion Pharmaceuticals Stock analysis

When running Hepion Pharmaceuticals price analysis, check to measure Hepion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hepion Pharmaceuticals is operating at the current time. Most of Hepion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Hepion Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Hepion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Hepion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Equity Valuation
Check real value of public entities based on technical and fundamental data
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
The market value of Hepion Pharmaceuticals is measured differently than its book value, which is the value of Hepion that is recorded on the company's balance sheet. Investors also form their own opinion of Hepion Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Hepion Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hepion Pharmaceuticals' market value can be influenced by many factors that don't directly affect Hepion Pharmaceuticals underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Hepion Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Hepion Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hepion Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.